MIT Sloan BioInnovations Conference
February 24, 2012
Boston Marriott Cambridge Hotel
Kendall Square, Cambridge MA

Panel 1: Personalized Medicine

Domenick Bertelli, Moderator

Domenick Bertelli is a partner at Putnam Associates where he serves large and mid-sized biopharmaceutical clients and venture-backed startups on growth strategies, therapeutic area strategies, franchise strategies, and pricing and reimbursement. His clients include several blockbuster products, and many specialty and orphan drug franchises. Prior to Putnam, Domenick was an Engagement Manager at McKinsey & Company, and an investment banker at BT Alex.Brown. Domenick earned his MBA in New Product and Venture Development from the MIT Sloan School of Management, and his AB in Government from Harvard.

Donald A. Bergstrom, MD, PhD, Panelist

Donald Bergstrom joined Sanofi-Aventis oncology in May 2010 as Associate Vice President and Global Head of Translational and Experimental Medicine, where he leads a team of laboratory and clinical scientists who integrate translational science into oncology drug development to ultimately improve the care of patients with cancer. The group is dedicated to molecular understanding of pre-clinical models on which decisions to pursue clinical development are based, and then designing clinical research strategies to most closely mimic the successful pre-clinical program. Prior to joining sanofi, Bergstrom spent 6 years at Merck Research labs where he held roles of increasing responsibility in the Clinical Molecular Profiling, Oncology Clinical Research and Experimental Medicine Oncology groups. Prior to joining industry he completed his MD degree at the University of Washington and his PhD and post-doctoral training at the Fred Hutchinson Cancer Research Center, both in Seattle, WA. He was a resident in Clinical Pathology at the University of Washington.

Kevin Krenitsky, MD, Panelist

Dr. Krenitsky joined Foundation Medicine as Chief Operating Officer in June 2011, bringing 15 years of experience in building and managing global diagnostic and biotechnology operations to the company. He joins Foundation Medicine from Enzo Clinical Labs where he served as president. In this role, he instituted a comprehensive operational plan that resulted in re-accreditation by the College of American Pathologists and led the introduction of numerous U.S. FDA-approved esoteric tests as well as several new laboratory developed test rollouts, all of which led to significant revenue growth during his tenure.

Prior to Enzo Clinical Labs, he was chief executive officer at BioServe Biotechnologies, a global biotechnology company specializing in processing genetic diagnostic tests, and before that, he served as chief executive officer at Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. Before joining Parkway Clinical Laboratories, Dr. Krenitsky held multiple senior level positions within Genomics Collaborative, Inc. (a SeraCare Life Sciences Company), a full-scale clinical and genomics research company.

Dr. Krenitsky received a B.S. in business management from the University of Scranton and an M.D. from Jefferson Medical College.

Scott Allocco, Panelist

Scott Allocco is the President and a co-founder of BioMarker Strategies, an emerging growth cancer diagnostics company that is developing the SnapPath(tm) live tumor cell testing system. SnapPath(tm) enables predictive, ex vivo diagnostics for targeted therapies that are not possible using dead, fixed tumor tissue.

As President of the company, Mr. Allocco coordinates all fundraising, external relations, strategic partnerships, communications and regulatory affairs for the company. He is also an active member of the Personalized Medicine Coalition (PMC), the BIO Personalized Medicine and Molecular Diagnostics Committee, and ADVAMED Dx, where he is actively engaged in efforts to reform FDA regulatory and CMS reimbursement policies for next generation biomarker tests, including companion diagnostics.

Prior to founding BioMarker Strategies, he had 15 years of healthcare and pharmaceutical industry experience, including drug coverage and reimbursement issues for commercial and public sector health insurance programs. Most recently, Mr. Allocco was Vice President of State Government Relations for Coventry Health Care, one of the nation's largest health insurance companies. He was also Vice President for Business Development and Government Affairs at First Health Services, which he helped build into the nation's largest pharmacy benefits administrator of Medicaid drug-benefit programs.

Prior to joining First Health Services, Mr. Allocco was a Managing Director in the health public affairs group at Hill and Knowlton's Washington, D.C. office. He also served for four years as the Director of the Office of Government Affairs for the New Jersey Department of Health and Senior Services under Governor Christine Todd Whitman. He graduated from Hamilton College.

Panel 2: Healthcare Investing

Jonathan Fleming, Moderator

Jonathan Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut.

Mr. Fleming has been in the investment business for over twenty years, starting and financing growth companies in the United States, Europe, and Israel. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming holds a Master's degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.

Mr. Fleming is a director of several private companies including Dicerna Pharmaceuticals, Lab Partners, Radius Pharmaceuticals, Avaxia Pharmaceuticals and Railrunner. He is also a director of Leerink Swann, a Boston based investment bank specializing in healthcare companies. Mr. Fleming is a Trustee of the Museum of Science in Boston, a Member of the Board of NEHI, a healthcare oriented think tank and policy advocacy group, and he is on the Scientific Advisory Board of the Massachusetts Life Science Center. In addition, Mr. Fleming is a Senior Lecturer at the MIT Sloan School of Business.

Michelle Browner, PhD, Panelist

Before joining Enlight Biosciences as CEO and member of the Board, Michelle was at Roche Pharmaceuticals where most recently she served as Global Head of Emerging Science and Technologies in Pharma Partnering and where she was formerly Global Head of Pharma Research Strategy. As Vice President, Discovery Technologies at Roche Palo Alto she contributed to a number of projects that advanced into the clinic and late stage development. Michelle earned her Ph.D. in Cell Biology from Baylor College of Medicine and graduated with high honors in Biology from Kenyon College.

Jean George, Panelist

Jean is Advanced Technology Ventures East Coast lead partner for healthcare investments and has been with ATV since 2002. She focuses on the life sciences and therapeutic device markets, identifying innovations viable for commercialization.

Jean represents ATV on the boards of Acceleron Pharma, Calithera Biosciences, Five Prime Therapeutics, Hydra Biosciences, Portola Pharmaceuticals, Verastem, and Zeltiq Aesthetics (NASDAQ: ZLTQ). She also was on the boards of Hypnion, prior to its acquisition by Eli Lilly in April 2007; Proteolix, prior to its acquisition by Onyx Pharmaceuticals in November 2009; and Critical Therapeutics (NASDAQ:CRTX). She has been featured on the Forbes Midas List and was formerly a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center.

Jean has been in the biopharmaceutical industry for over 20 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of global sales and marketing. She also was Vice President and founder of Genzyme's Tissue Repair Division, where she was responsible for identifying new product opportunities and potential acquisition candidates.

Jean joined BancBoston Ventures in 1998 to lead its life sciences investments. There she led investments in Neurometrix (NASDAQ: NURU), Ironwood Pharmaceuticals (formerly Microbia) (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters), and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Previously, Jean spent six years working in chemistry and bioresearch. She earned an M.B.A. from Simmons College Graduate School of Management and a B.S. from the University of Maine.

Amir Nashat, Panelist

Amir Nashat is a partner in our Boston office. Amir joined Polaris in April 2002 and focuses on investments in the life sciences, consumer products and energy.

Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. During his time at MIT, Amir completed an internship in the London office of Goldman, Sachs & Company. Prior to MIT, Amir earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.

Amir has served as the initial CEO of Living Proof (known as Andora at the time), and Sun Catalytix Corporation. Amir currently represents Polaris as a Director of aTyr Pharmaceuticals, Avila Therapeutics, BIND Biosciences, Fate Therapeutics, L1 Agrosciences, Living Proof, Pervasis Therapeutics, Promedior Pharmaceuticals and Selecta Biosciences. Additionally, Amir has served as a Director of Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired b Bayer), and is currently an Observer of GI Dynamics (GID.AX).

Amir serves on the Board of the New England Venture Capital Association, the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT.

Panel 3: Value Network and Open Innovation Business Models in Pharma

Matthias Evers, Moderator

Matthias Evers is a Principal in McKinsey's Hamburg office and a co-leader of the EMEA Pharmaceuticals and Medical Products R&D-Medical Practice. He engaged clients in Europe, the US and Asia on transforming R&D organizations to overcome productivity and innovation hurdles. His particular interest lies in developing innovative R&D models and collaborations, within and across companies / other stakeholders, and leading performance transformations both in Research and Development. He has been crafting DA / TA level portfolio strategies and clinical strategies for individual assets. He holds a Ph.D., in Biochemistry with focus on Neuroscience from the Ruhr University Bochum, Germany and authored various peer-reviewed articles in neuroscience and molecular biology / bioinformatics.

Jens Oliver Funk, MD, Panelist

Jens Oliver Funk, MD, Senior Vice President, is Global Head of the Therapeutic Area Oncology in Merck Serono R&D. He is responsible for the Oncology discovery portfolio, including basic and translational research as well as biomarker discovery for all Oncology R&D projects. Together with his global team in Boston and Darmstadt he has brought more than ten new biologics and small molecules into clinical development. He is also part of the leadership team that steers the proof-of-concept and development strategy for the clinical portfolio. Dr. Funk held various senior leadership positions within Preclinical R&D at Merck KGaA, before taking responsibility for the TA Oncology within Merck Serono at the beginning of 2007.

Jens Oliver Funk studied Medicine in Lubeck, Edinburgh, and Stanford, and holds a Board Certification and Professorship in Clinical and Molecular Dermatology. His focus has been on basic and translational cancer research in several fields. Prior to joining Merck KGaA in 2002, Dr. Funk worked in various research and clinical positions at renowned cancer research centers in Munich, Erlangen, San Francisco, and Seattle.

Richard J. Gregory, Ph.D, Panelist

Dr. Gregory is Senior Vice President and Head of Research at Genzyme. He received his Ph.D. in Biochemistry from the University of Massachusetts at Amherst in 1986, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology in Shrewsbury MA. In 1989 he joined Genzyme Corporation, where he was responsible for a number of discovery projects in the molecular biology department. In 1990, his group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) and to determine the molecular defect caused by the most common mutation of CFTR. Richard received the Genzyme President's award for this work in 1991. This research on the molecular basis of cystic fibrosis led to the development of Genzyme's CF gene therapy program, for which Richard was Project Team Leader until 1993. From 1993 to 1995 he was Director of Molecular Biology at Canji, Inc. in San Diego, where he conducted research on development of gene therapies for cancer. Dr. Gregory returned to Genzyme in 1995 to head the gene therapy program as Vice President for Gene Therapy. Research efforts under Dr. Gregory's direction during this period included programs in cancer immunotherapy, gene therapies for genetic diseases and cardiovascular gene therapy. In 2003 Richard was appointed Head of Research for Genzyme Corporation. In 2011, following the acquisition of Genzyme by Sanofi, he became Head of the Genzyme R&D Center, a unit of Sanofi Global R&D. He is the co-author of over 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology.

Adrian Gottschalk, Panelist

Adrian Gottschalk is a Vice President, Global Commercial Strategy in Biogen Idec. Adrian joined Biogen Idec in June of 2004 and worked initially in Biogen Idec's Corporate Strategy group in Cambridge focusing on issues from biosimilars, small molecule strategy to small product strategies. He has held numerous leadership roles at Biogen Idec, including in commercial strategy and operations, and he has worked in Boston and San Diego. Adrian is currently Vice President of the Global Commercial Strategy group, which is responsible for global brand marketing & commercial strategy across all marketed and pipeline products for the U.S., Europe, and Emerging Market affiliates.

Adrian holds a B.S. in biochemistry from Texas A&M University in College Station, Texas and is a graduate of the Sloan School of Management at MIT and the joint Harvard Medical School / MIT Biomedical Enterprise Program where he received his M.B.A. and Sc.M. degrees, respectively. Prior to graduate school Adrian worked as a consultant for Price Waterhouse in their upstream petroleum information technology consulting group in Dallas, Texas. Adrian is originally from Johannesburg, South Africa and grew up in Dallas, Texas.

Frank Deane, PhD, Panelist

Frank Deane, Ph.D., is a director and founder of Lumleian, based in Boston, MA. Lumleian provides decision support to life-science clients, including: academia and research institutions, bio-pharmaceutical companies, and life-science investors. To offer both the requisite breadth and depth of expertise required by modern R&D; decision makers, Lumleian has pioneered a unique business model grounded in real-time knowledge management and expertise based teams, including 30+ clinicians and Ph.D. scientists. Leveraging this platform, Lumleian aspires to provide clients with best in class decision support in portfolio optimization, in-licensing and out-licensing strategy, clinical development strategy, and asset valuation.

Frank has over 10 years of experience in working with life-science companies. Prior to founding Lumleian, Frank was a director with Leerink Swann and a case team leader with Bain and Company. Frank entered consulting after spending three years in the bio-pharmaceutical industry with Eli Lilly, supporting portfolio optimization and business unit strategic planning. He began his career, as a quantitative risk analyst working at BlackRock. Frank earned a Ph.D. in econometrics from the Krannert School of Management at Purdue University, where his dissertation focused on applying game theory and statistics to optimize resource allocation. Frank has an A.B in economics from Princeton University. Frank is an Eagle Scout, inconsistent tennis player, mediocre skier, husband and father of two inquisitive, albeit rambunctious, toddlers. He serves on the board of directors at St. Paul School in Hingham, MA.

Panel 4: Emerging Markets

Mohan Bala, MBA, PhD, Moderator

Mohan Bala joined Sanofi as the Head of Oncology Market Access in 2010. In his role he is responsible for ensuring that all Sanofi oncology products have strong value propositions that is supported by robust evidence. Prior to joining Sanofi Mohan held positions of increasing responsibility in the areas of Health Economics and reimbursement at Johnson & Johnson and GlaxoSmithKline. Prior to joining industry Mohan spent 4 years as a healthcare consultant. Mohan holds an MBA and PhD from the University of Chicago. He is also the author of over 50 peer reviewed publications in the areas of Health Economics and Health Policy.

Monika A. Vnuk, MD, Panelist

Dr. Monika A. Vnuk is a Senior Director, Worldwide Business Development, at Pfizer. In her role, Dr. Vnuk focuses on transaction execution, including leading multi-functional teams through deal and negotiation processes. Since joining Pfizer in 2008, Dr. Vnuk participated in many, and completed several, partnering and merger and acquisition transactions. Before joining Pfizer, Dr. Monika A. Vnuk was a vice president at Banc of America securities. Prior to her position at Banc of America, she was a Principal at Oxford Bioscience Partners. Prior to that job, Dr. Vnuk was a Fellow at the Health Care Entrepreneurship Program at Boston University. She has experience in the healthcare data industry where she completed internships with Quintiles Transnational and McKesson HBOC. Dr. Vnuk is a 2000 Inductee to the Alpha Omega Alpha Medical Honor Society. Dr. Vnuk holds a B.A. in Mathematics and Philosophy from Boston University and an M.D. from Boston University School of Medicine.

Michael N. Chang, Ph.D., Panelist

Dr. Chang is the founder of Optimer Pharmaceuticals, Inc., and served as its president and CEO until June, 2010. Optimer is a commercial stage biotechnology company focused on developing innovative medicine for the treatment of challenging diseases. In this role, Dr. Chang raised 75 million in venture capital, developed its platform technology - OPOpS. He also led the team in developing two new antibiotics - Fidaxomicin and Prulifloxacin, taking it all the way to NDA submission. In addition, Dr. Chang successfully took the company IPO in 2007(listed on NASDAQ as OPTR), and since raised 250 million US dollars for the company. In addition, several other exciting clinical candidates in the area of cancer, infectious disease, has also been developed under his leadership.

Before joining Optimer as CEO, Dr. Chang served as the Senior Vice President of R & D, Pharmanex, Inc., and Chief Scientific Officer of Nu Skin Enterprises (NYSE: NUS) from 1994 to 2001. Dr. Chang was the founder of Pharmanex, Inc., a leading nutritional supplement company in the USA. Pharmanex was sold to Nu Skin Enterprise in 1998, and continued its operation independently, and achieved annual worldwide sales of 900 million US dollars in 2009.

Before founding Pharmanex, Dr. Chang worked for 15 years in pharmaceutical industry. He started his career at Merck in 1979, and was the Associate Director of Medicinal Chemistry when he left in 1988. He then joined Rhone-Poulenc Rorer Director of Drug Discovery until 1994, where he led his team in developing three multi-billion dollar drugs - Texotere, Lovanox and Sinercid.

Dr. Chang earned his Ph.D degree in Organic Chemistry from Brandeis University in 1978, and did his Post-doctoral training at MIT. Dr. Chang holds 37 US patents and 65 peer-reviewed publications.

Dr. Albert Bourla, Panelist

As President & General Manager of Pfizer's Established Products Business Unit, Albert supervises the development and implementation of strategies and tactics related with the entire off patent portfolio of the company (including legacy brands and Generic products) for which he has the overall P&L responsibility.

Before assuming his current position, Albert was leading the Animal Health operations in a large portion of the world as Area President for Europe, Africa, Asia & Pacific, Albert has extensive functional and geographical experience and has relocated with Pfizer in different parts of the world 8 times since joining in 1993. He has worked in positions of increasing responsibility beginning as a Technical Director in Greece, Marketing Director in Eastern Europe, General Manager in Poland, and Regional Director of Central and Eastern Europe. In 2001, he moved to global headquarters in New York City. In 2004 he became Vice President of Business Development and New Products Marketing. In this capacity he supervised Pfizer Global Animal Health licensing and acquisition activities as well as the prioritization of Pfizer's R&D portfolio. In 2006, as Area President of Europe, Africa and Middle East he relocated the European headquarters from New York to Paris. In 2010 he relocated back to NY to assume his current responsibilities.

Before joining Pfizer, Albert was a scientific collaborator in the Veterinary School of Aristotle University, in Greece. He is a qualified veterinary surgeon and holds a PhD degree in Reproduction.

Douglas M. Hansell, MD, MPH, Panelist

Dr. Douglas M. Hansell joined GE Healthcare as Chief Medical Officer of the Americas in December 2010. Dr. Hansell works to develop and advance the medical and scientific strategy of GEHC working with healthcare providers, medical societies, advocacy groups, regulators and governments in the America's region.

Prior to joining GEHC, Dr. Hansell was the Chief Medical Officer of Respiratory and Patient Monitoring at Covidien. There, he built and managed the Medical Affairs, Clinical Research Affairs, Healthcare Economics & Reimbursement, and Medical Education groups. While at Covidien, he developed the medical strategy for the business unit. He built relationships with key global policy and provider stakeholders. He was involved with two significant acquisitions and tripled the number of clinical trials under management.

Prior to joining Covidien, Dr. Hansell was a managing director with Intrepis, a medical strategy firm serving healthcare companies, academia and the investment community. He assisted client management teams with strategy, growth initiatives and clinical development of early stage technologies. Additionally, Dr. Hansell has advised leading academic organizations, assisting with technology transfer and entrepreneurial program development.

Prior to Intrepis, Dr. Hansell was Chief Medical Officer, Vice President of Medical Affairs at Biopure. He also founded a healthcare technology company focused on electronic prescribing. Earlier in his career, Dr. Hansell gained executive experience leading hospital organizations. Dr. Hansell served as Chief Medical Officer of Emerson Health System in Massachusetts and led care and operational redesign at Massachusetts General Hospital / Partners Healthsystem in Boston in the 1990's.

For the past 20 years, Dr. Hansell has also maintained an active clinical practice in Anesthesiology at Massachusetts General Hospital in Boston and has held teaching appointments at Harvard University. He is board certified in Internal Medicine and Anesthesiology, fellowship trained in cardiovascular anesthesia and experienced in critical care medicine.

Dr. Hansell received his BS in Chemistry and his MD degree from the University of Illinois. He completed his Internal Medicine training at Barnes Hospital/Washington University, his Anesthesiology training and cardiovascular fellowship at Massachusetts General Hospital/Harvard University. He completed his Masters in Public Health at Harvard University.

Rogério Vivaldi, MD, MBA, Panelist

Rogério Vivaldi, MD, MBA joined Genzyme in 1994 and has held positions of increasing responsibility over his career with the company. Prior to his recent appointment as Head of Rare Disease Business Unit for Genzyme, a Sanofi company, Rogério was President of Genzyme's Renal and Endocrinology Business. He previously served as Senior Vice President and President of Genzyme Latin America, responsible for the company's significant growth and diversification in the region, after founding Genzyme in Brazil.

Rogério was the first Brazilian doctor to treat a patient with Gaucher disease with enzyme replacement therapy in 1992 and has authored several publications on Gaucher disease. He was the founding partner of the Latin American Group on Gaucher. Rogério received his medical degree from Universidade do Rio de Janeiro Medical School, and received his MBA degree from Copead—Universidade Federal do Rio de Janeiro.